G. Créhange

Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial

Thierry Conroy, Marie‐Pierre Galais, Jean‐Luc Raoul et al. · The Lancet Oncology · 2014 · 446 citations

Medicine, Oncology, Radiation Oncology +15

Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial

C. Carrié, Ali Hasbini, Guy de Laroche et al. · The Lancet Oncology · 2016 · 361 citations

Medicine, Oncology, Urology +15

Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial

C. Carrié, Nicolas Magné, Patricia Burban-Provost et al. · The Lancet Oncology · 2019 · 250 citations · Full text

Medicine, Oncology, Urology +16

Optimized fractionated radiotherapy with anti-PD-L1 and anti-TIGIT: a promising new combination

M. Grapin, Corentin Richard, Emeric Limagne et al. · Journal for ImmunoTherapy of Cancer · 2019 · 210 citations · Full text

Medicine, Oncology, Radiation Oncology +17

Role of STAT3 in CD4+CD25+FOXP3+ Regulatory Lymphocyte Generation: Implications in Graft-versus-Host Disease and Antitumor Immunity

Jean‐René Pallandre, Emilie Brillard, G. Créhange et al. · The Journal of Immunology · 2007 · 152 citations

Life Sciences, Cell Biology, Immunology +17